Search Results

You are looking at 21 - 30 of 551 items for :

  • neuroendocrine cancer x
  • All content x
Clear All
Free access

Jennifer L Bishop, Alastair Davies, Kirsi Ketola, and Amina Zoubeidi

the emergence of cancer stem-like cells (CSCs), epithelial–mesenchymal or myeloid plasticity, and neuroendocrine transdifferentiation, which may contribute to disease progression. A clear understanding of these processes will help guide novel

Free access

Germano Gaudenzi, Silvia Carra, Alessandra Dicitore, Maria Celeste Cantone, Luca Persani, and Giovanni Vitale

predisposition to cancer development, in particular tumors of the CNS or gastrointestinal tract and malignant peripheral nerve sheath tumors (MPNSTs) ( Shin et al . 2012 ). Although it has not been reported if these tumors have a neuroendocrine phenotype

Free access

A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, A Angeli, and L Dogliotti

. Understanding mechanisms underlying the development of hormone refractoriness is the basis for developing new treatment strategies for the disease at this stage. The majority of conventional prostate cancers display at diagnosis focal neuroendocrine (NE

Free access

Giovanni Vitale, Germano Gaudenzi, Luisa Circelli, Marco F Manzoni, Andrea Bassi, Niccolò Fioritti, Antongiulio Faggiano, Annamaria Colao, and on behalf of NIKE Group

Introduction Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour originating from parafollicular C cells. At the end of 60s, after the discovery that MTC represents a unique thyroid cancer, it was recognised that the tumour occurred

Restricted access

Salma Ben-Salem, Varadha Balaji Venkadakrishnan, and Hannelore V Heemers

In this research letter, we provide a brief report analyzing the relationship between genomic alterations and cell cycle-related genes in prostate cancer (CaP) as a companion to our review on this topic also published in this issue of Endocrine

Free access

Bristi Basu, Bhawna Sirohi, and Pippa Corrie

Introduction Malignant neuroendocrine tumours (NETs) are rare, comprising ∼2% of all malignant tumours diagnosed in the western world. They can arise from neuroendocrine cells anywhere in the body and form a spectrum of cancers that vary in

Free access

Kosmas Daskalakis, Olov Norlén, Andreas Karakatsanis, Per Hellman, Rolf Larsson, Peter Nygren, and Peter Stålberg

(XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology 59 637 – 642 . ( ) 10.1007/s00280-006-0306-6 16937105 Bjersand K Mahteme H

Free access

Zhihong Chen, Lora W Forman, Kenneth A Miller, Brandon English, Asami Takashima, Regine A Bohacek, Robert M Williams, and Douglas V Faller

-specific susceptibility, designated ‘Ras-mediated apoptosis’, can be exploited as a targeted cancer therapeutic. Bronchopulmonary, gastrointestinal, and pancreatic neuroendocrine tumors are rare tumors originating from neuroendocrine tissues ( Oberg 1999 ). Clinical

Free access

Tessa Brabander, Julie Nonnekens, and Johannes Hofland

Kwekkeboom DJ 2017 Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors . Clinical Cancer Research 23 . (

Free access

Amy Moreno, Argun Akcakanat, Mark F Munsell, Alpana Soni, James C Yao, and Funda Meric-Bernstam

tumors ( Yao 2007 ). In preclinical work, cancer cells with activation of PI3K/Akt signaling, regardless of mechanism of activation, have shown sensitivity to rapamycin ( Noh et al . 2004 ). Shah et al . (2006) reported that 76% of the neuroendocrine